ExpreS²ion - Annual report for 2022 published

Hørsholm, Denmark, 2 May 2023 – ExpreS²ion Biotech Holding AB (“ExpreS²ion”) hereby announces that the company’s annual report for the financial year 2022 is published. The annual report is available as an attachment and on ExpreS²ion’s website at the following address (https://investor.expres2ionbio.com/reports/).

The Swedish version of the Annual Report is the version that the Company’s Auditors have reviewed, as clarified in the Auditor’s Report included at the end of the report. As such, in the case of differences between the Swedish and English versions, the Swedish version prevails.

Certified Adviser
Svensk Kapitalmarknadsgranskning AB

For further information about ExpreS²ion, please contact:
Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail: buf@expres2ionbio.com

Keith Alexander, CFO
Telephone: +45 5131 8147
E-mail: ka@expres2ionbio.com

About ExpreS²ion
ExpreS²ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS²ion Biotech Holding AB with company register number 559033-3729. ExpreS²ion has developed a unique technology platform, ExpreS², for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS² is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS²ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS²ion owns 34%. For additional information, please visit www.expres2ionbio.com.